Skip to content

Comparison of the efficacy of intravenous paracetamol versus intravenous dexamethasone and intravenous morphine for the emergency department treatment of acute migraine headache

Comparison of the efficacy of intravenous paracetamol versus intravenous dexamethasone and intravenous morphine for the emergency department treatment of acute migraine headache

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201405217327N4
Enrollment
270
Registered
2014-09-30
Start date
2014-06-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute migraine headache. Migraine

Interventions

Intervention 1: Intervention group: 1 gram acetaminophen will be soluted in 100 cc normal saline and will be infused in 10 minutes as a single dose. Drug name: Apotel, 1 g/6.7ml Chemical compound: Ac
Treatment - Drugs
Intervention group: 1 gram acetaminophen will be soluted in 100 cc normal saline and will be infused in 10 minutes as a single dose. Drug name: Apotel, 1 g/6.7ml Chemical compound: Acetaminophen C
Control group: Morphine with 0.1 mg/kg dosage will be soluted in 100 cc normal saline and will be infused in 10 minutes as a single dose in order to simulation. Drug name: Morphin, 10 mg/ml Injection
Control group: 8 milligram dexamethasone will be soluted in 100 cc normal saline and will be infused in 10 minutes as a single dose in order to simulation. Drug name: Dexamethasone, 8 mg/ml Chemical

Sponsors

Student Research Committee
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria : the patients between 18 and 60 year old without any history of neurologic disorder with at least one experience of migraine headache and 4 criteria of 12 criteria of Vascular symptoms. Exclusion criteria : pregnancy; history of neurologic disorder; patients without self consent; Body temperature more than 37.7 C; diastolic blood pressure more than 105 mm Hg.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Pain intensity of the acute migrane head ache. Timepoint: Before treatment, 10 minutes after the begining of treatment, 20 minutes after the begining of the treatment, 30 minutes after the begining of the treatment, 24 hours after the begining of the treatment. Method of measurement: Visual analoge score, Intensity of the pain in proportion to millimetr from 0 to 100 will be measured.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Samad Shams Vahdati

Tabriz University of Medical Sciences

Shams@tbzmed.ac.ir+98 914 115 6941

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026